At BSS, we’re dedicated to improving lives by expanding access to biologics. Product pipeline with CLEAR IP, DEFINE REGULATORY PATHWAY, KNOW CLINICAL DESIGNED, EVIDENCE OF PATIENT SAFETY with strict adherence to Global Regulatory ( FDA, EMA) Advice
Our robust pipeline is bringing high-value treatments to patients in need. We have the assets, expertise, and insights to bring high-quality products to patients around the world.
$2.8 Billion combined US addressable market (PEG GCSF, GCSF, Rituximab)
$56 Million in development and facility costs subsidized with nearly $40 Million in tax credits and grants - Located in Opportunity Zone
$280 Million cumulative gross revenue in the first full pipeline year (2027)
$664 Million cumulative gross revenue first 3 years of market launch (through 2027)
Biosimilar company with world class Scientific, Manufacturing, and Commercial capabilities at the Executive and Operator level.
Unique and progressive partnership agreement with $65B biologics developer that enables access to 14 biologic candidates and $50M in cost sharing.
Low risk 3 product portfolio launching into large growing markets.
Optimized for low-cost delivery model and investor return on capital.